Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics IncfiledCriticalAxsome Therapeutics Inc
Publication of AR122344A1publicationCriticalpatent/AR122344A1/en
En el presente documento se describen métodos para tratar la narcolepsia con cataplejía, que comprenden administrar reboxetina (incluida esreboxetina) a un ser humano que lo necesite. La reboxetina (incluida la esreboxetina) también se puede utilizar en la fabricación de un medicamento para el tratamiento de la narcolepsia con cataplejía. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina (incluida esreboxetina) e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplejía en un ser humano.Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human in need thereof. Reboxetine (including esreboxetine) can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions for using the pharmaceutical composition to treat narcolepsy with cataplexy in a human.
ARP200103359A2019-12-032020-12-02
USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
AR122344A1
(en)
method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin